Several research teams in the United States and the United Kingdom are currently requesting regulatory approval for techniques that would result in inheritable genetic modification (changes that would be passed on to future generations).
Alert: The US Food and Drug Administration has scheduled a public meeting that will include discussion of these "mitochondria replacement" techniques on October 22 and 23 [Due to the government shutdown, this meeting has been POSTPONED. Check back here for updates.] You can submit written comments until October 15. Instructions are on the FDA website, here. See the letter CGS submitted, here.
Mitochondria replacement techniques would be used to attempt allowing a small number of women with a rare kind of severe mitochondrial disease to have a healthy and mostly genetically related child. The techniques work by combining parts of an affected woman's extracted egg with parts from the egg of another woman. The child would thus be genetically related to three people, which is why the media often refers to "three-parent babies" or "three-parent in vitro fertilization."
Critical questions about safety and efficacy have not been answered, and these techniques raise profoundly important social and ethical questions. A strong and long-standing international consensus against inheritable genetic modification currently exists, along with explicit prohibitions in dozens of countries. No country has ever given regulatory approval for inheritable genetic modification, and yet both the United States and the United Kingdom are contemplating that right now. If approval is given, and the bright line established by this international consensus is crossed, it could open the door to more and different kinds of inheritable genetic modifications in the future, potentially leading to the genetic "redesign" of future generations.
To quickly get up-to-date on the current events, please see:
- Proposed Treatment To Fix Genetic Diseases Raises Ethical Issues, NPR, October 09, 2013
- A slippery slope to human germline modification, Nature, by Marcy Darnovsky, July 9, 2013
- The British Embryo Authority and the Chamber of Eugenics, Huffington Post, by Stuart Newman, March 11, 2013
- Brave New Cells?, Project Syndicate, by Donna Dickenson, December 29, 2012
For much more information and an extensive resource library, please see below.
1. What is mitochondria replacement? Why is it being explored?
2. What is the state of the research?
3. What concerns does mitochondria replacement raise?
4. Frequently Asked Questions
- Articles and commentary:
- CGS's press statements (June 27 2013, March 20 2013, Dec 19 2012)
- Statement from 34 members of the Parliamentary Assembly of the Council of Europe stating that this technique "is incompatible with human dignity and international law."
- "Alarm Over Genetic Control of Embryos Times 20 March 2013," a letter to The Times (UK) citing grave reservations about mitochondria replacement signed by 30 bioethicists from around the world
- "Eugenics fear over gene modification,"a Letter to the Editor in The Guardian signed by 15 scholars and activists
- "On Designer Babies," Tufts Medicine, by Professor of Humanities and Social Sciences at Tufts University and an adjunct professor of public health and community medicine, Sheldon Krimsky
- "A slippery slope to human germline modification," Nature, by CGS's executive director, Marcy Darnovsky
- "A Former IVF Baby on "Three-Parent IVF"," Huffington Post, by CGS's Program Associate, Jessica Cussins
- "Brave New Cells?" Project Syndicate, by Emeritus Professor of Medical Ethics and Humanities at the University of London, Donna Dickenson
- "The British Embryo Authority and the Chamber of Eugenics," Huffington Post, by Professor of Cell Biology and Anatomy, New York Medical College, Stuart Newman
- "The ethics of creating children with three genetic parents," Reproductive BioMedicine Online, by Françoise Baylis
- "Three person IVF," University of Oxford's Practical Ethics by Paula Boddington, Lecturer in Philosophy at Oxford
- "The ethics of three-genetic-parent embryos," Ottawa Citizen, by Margaret Somerville
- "Geneticists Breach Ethical Taboo By Changing Genes Across Generations," NPR, by Rob Stein
- "Lord Robert Winston Warning Over Child ‘Eugenics’," The Scotsman, by Lyndsay Buckland
- "The Eugenic Impulse," The Chronicle of Higher Education, by Nathaniel Comfort
- "My concerns about Nature paper on Genome Transfer for mitochondrial disease," the Knoepfler Lab Stem Cell Blog, by Paul Knoepfler
- "Exaggerations and Misrepresentations have no place in Science Policy Debates," the Council for Responsible Genetics
- "Three parents? Sorry, but this is science gone mad", The Telegraph, by Melanie McDonagh
- "Three-Parent" Babies: Ten Reasons Why We Need a Global Moratorium Now [pdf], an alert from Mothers for a Human Future
- "Genetically Modified Babies," peggyomara.com, by Peggy O'Mara
- "Ethics of mitochondrial gene replacement: from bench to bedside," BMJ, by Annelien L Bredenoord and Peter Braude
- Letters submitted to the HFEA's mitochondria replacement public consultation:
- Biopolitical Times blogs on mitochondria replacement:
What is mitochondria replacement? Why is it being explored?
Mitochondria are tiny organelles found in the cytoplasm of all living
cells possessing cell membranes, including all animal and plant cells.
They play important roles in helping regulate cellular energy use and
cell growth. Mitochondria are of special interest because they possess
their own genome, independent of the main cellular genome housed in the
Mitochondria are responsible for producing more than 90% of the energy
needed in our bodies; failures of this system through inherited or
spontaneous mutations of mitochondrial DNA (mtDNA) or nuclear DNA (nDNA)
can cause damage to the brain, liver, heart, skeletal muscles, kidney,
and the endocrine and respiratory systems. Because mitochondria play
such a complex role in our bodies, performing different functions in
different tissues, there are hundreds of different mitochondrial
diseases. Mitochondrial disease often affects children, but is also common in adults due to deteriorating mitochondrial
function with age. Mitochondrial disease is known to affect around 1 in 5,000–10,000
Mitochondria replacement is a new approach that is being
researched with the goal of allowing a woman who has mutations in her
mtDNA to lessen the risk of passing on inherited mitochondrial disease
to her child. The techniques being developed are variations on combining the nuclear DNA from an egg of an affected woman with the mtDNA of an unaffected woman's egg. A resulting child would possess genes from three adults, and this altered genome would be passed on to succeeding generations.
Several mitochondria replacement techniques are currently being developed by researchers who have announced some success in animals and in human zygotes, but have not yet transferred genetically altered embryos into a woman.
The techniques being investigated could only be attempted in a minority of the cases of mitochondrial disease. They would not be applicable to mitochondrial disease that is caused by nuclear DNA, which makes up the majority of cases, nor would they prevent mitochondrial disease that arises due to spontaneous mutations or deterioration with age. The techniques
Pronuclear Transfer (PNT)
(See diagram here)
Pronuclear transfer begins with an embryo created via in vitro fertilization, using the intended parents’ sperm and eggs. Simultaneously, a second embryo is created using a donor egg with healthy mitochondria and the father’s (or donor) sperm. When the embryos are one day old, still at the single-cell stage, the pronuclei are removed from the first embryo. The majority of the mother’s mutated mitochondria are left behind in the enucleated embryo, which is discarded. Meanwhile, the pronuclei of the second embryo are removed and discarded. The parents’ pronuclei are then placed into the second embryo, which has maintained the healthy mitochondria from the donor’s egg. This constructed embryo can continue to develop and then be transferred into the mother.
Researchers at Newcastle University, where PNT is being developed, acknowledge that the technique is not ready to go to clinical trial (1, 2, 3, 4). They plan to undertake follow-up work that was requested by the HFEA, but the center where they will do so opened in September 2012 and no results have yet been reported. There have been no published results of using PNT in non-human primates, nor of human embryos produced with PNT developing past an early stage.
Maternal Spindle Transfer (MST)
(See diagram here)
In this technique, nuclear DNA is removed from the intended mother’s egg; the rest of the egg is discarded, including the unhealthy mtDNA. The nuclear DNA of an egg from a woman with healthy mitochondria is removed at the same time, leaving her healthy mitochondria in the cytoplasm. The mother’s nuclear DNA is placed into the enucleated donor egg, which can then be fertilized with sperm from the father. The resulting embryo can then be transferred into the mother.
Researchers at Oregon Health and Science University have created rhesus macaque monkeys using maternal spindle transfer, but their published report of this study failed to consider several key aspects of safety. The monkeys were followed for only three years, not long enough to generate useful data since mitochondrial disease often develops late in life. And because the genetic alterations would be passed to subsequent generations, multi-generational safety data are needed.
In addition, a worrying difference has been noted between the study of MST on the rhesus macaques and the trials so far on human zygotes: More than half of the human MST zygotes had abnormalities that were not observed in the monkeys. Some experts believe that human oocytes are more sensitive to spindle manipulations than monkey oocytes, a significant variation that requires further study before MST is used in humans.
MST can also involve other kinds of errors. Genetic material can be lost during transfer; small amounts of mtDNA from the unhealthy egg can be transferred; a mismatch between foreign mtDNA and nuclear DNA can occur; and the segregation of mutated mtDNA to specific tissues may lead to a significant accumulation of the mutant load. Negative effects caused by any of these would not be reversible.
Nuclear Genome Transfer (NGT)
(See full report [pdf])
Nuclear genome transfer is essentially the same as MST. Scientists at Columbia University in New York, working with human eggs, developed a technique that avoided premature oocyte activation and thus increased success rates. (They did not fertilize the eggs, but did activate them via parthenogenesis.) NGT research is still in preliminary stages, and the researchers working on it recognize the need for studies on a larger number of samples, and on animal models. They also realize the need to publicly discuss patient needs, ethical considerations, and appropriate guidelines for the use of this procedure in assisted reproduction, if it were to be approved for human clinical trial.
[back to top]
What is the state of the research?
Newcastle University, UK
Researchers at Newcastle University have focused on pronuclear transfer in mice. The UK currently prohibits any modifications of the human germline, but the Newcastle researchers are asking that PNT clinical trials be made legal (1, 2, 3), arguing that the technique could help those who suffer from mitochondrial disease.
In 2008, the HFEA issued a report outlining additional tests the researchers would have to undertake before this could be considered. The university received a grant of over 4 million pounds from the Wellcome Trust to build a new Centre for Mitochondrial Research to continue PNT research, including testing on primates, but none has been completed to date.
The HFEA held a public consultation on mitochondria replacement at the end of 2012, largely motivated by Newcastle’s research, that has now been passed on to the UK Secretary of State for Health. He will draft regulations to be reviewed by Parliament that will determine whether or not the Newcastle researchers may proceed to human clinical trials, and if so under what conditions. The Newcastle researchers do not currently refer to their work as creating “three-parent babies” or as constituting inheritable genetic modification, although the HFEA is aware of these concerns and references them in its consultation.
Oregon Health and Science University
Researchers at Oregon Health and Science University (OHSU) have focused on maternal spindle transfer. They have created "three-parent blastocysts" and used them to generate embryonic stem cells, as a demonstration that the blastocysts could create a viable embryo and child. Three years ago, they used the same process in rhesus macaques, producing four live offspring, which appear to be healthy and developing normally.
The OHSU researchers are explicit about the fact that if this technique were used in humans, it would irreversibly alter the human germline. The FDA has in effect banned this kind of modification since 2001, when it ordered an end to unauthorized efforts using earlier mitochondria replacement techniques. The OHSU researchers have been privately funded to date. They are now asking the FDA to lift its restrictions, and to break from its long-standing position against funding research that results in modification of the human germline.
Columbia University, New York
In December 2012, Columbia University scientists, in conjunction with the New York Stem Cell Foundation, published a paper in Nature describing their results with what they refer to as “nuclear genome transfer.” Their technique represents a variation of MST, which they present as an improvement over PNT. Their paper, unlike the one by OHSU researchers, does not acknowledge that mitochondria replacement would constitute germline modification.
[back to top]
What concerns does mitochondria replacement raise?
The critical question of whether mitochondria replacement is safe has not yet been satisfactorily resolved, as the notes above, this article by a Professor of Cell Biology and Anatomy, and many reports such as this one in The Lancet, or this one [pdf] by Human Genetics Alert, make clear. There are many risks, including risk of epigenetic changes provoked by the oocyte transfer procedure, some of which may only cause problems later in life. Models based on one animal also have limited relevance to other species, including humans. Critically, we cannot establish the risks for human development without unethical experiments on humans.
Changing the human germline:
Mitochondria replacement would result in inheritable genetic modification. Altering the human germline is considered to be the most objectionable of genetic technologies and has constituted a bright line not to be crossed. Many bioethicists, scholars, and advocates from around the world have argued that mitochondria replacement does not justify crossing this line.
The 1966 United Nations International Covenant on Civil and Political Rights, which the US has signed and ratified (with some reservations), states in Article 7 that, "No one shall be subjected without his free consent to medical or scientific experimentation."
The 2004 European Union treaty establishing the European Constitution states in Article 63:
1. Everyone has the right to respect for his or her physical and mental integrity.
2. In the fields of medicine and biology, the following must be respected in particular: (a) the free and informed consent of the person concerned, according to the procedures laid down by law;
(b) the prohibition of eugenic practices, in particular those aiming at the selection of persons;
(c) the prohibition on making the human body and its parts as such a source of financial gain;
(d) the prohibition of the reproductive cloning of human beings.
The genetic modification of human embryos would violate these provisions.
Another concern with allowing germline modification, even in a limited form, is that it can create a "slippery slope"; if researchers are allowed to use it to limit the transmission of even a few specified diseases, why shouldn't its use be allowed to limit any disease? And if it is allowed to increase well-being by treating disease, why not allow it to increase well-being by "enhancing" non-disease traits? MtDNA plays a critical role in cellular energy production and it is conceivable that if mitochondria transfer were made legal that some would propose using it to increase the athletic ability, decrease the risk of obesity, or increase the longevity, for example, of their children.
For much more information on inheritable genetic modification, see here.
Implications for identity
A donation of mitochondrial DNA is certainly less of a genetic contribution than an entire egg or sperm, but it is likely to nonetheless have a very profound impact on a child’s life, including his or her sense of identity. If successful, this donation will allow them to live free of otherwise debilitating diseases. It is easy to imagine the human curiosity, gratitude, and connection one would feel to the person that made this possible. If the procedure is unsuccessful, the emotions and relationship between the child and parents, as well as the donor, could be particularly fraught.
Even if the procedure is successful, however, the child will be aware that his or her genetic make-up is, in some fundamental sense, different from that of children conceived from two parents. Further, it will be difficult to ever really know if the procedure was completely successful. Children who result from mtDNA procedures will need to be monitored throughout their lives for possible unanticipated effects. They will be, and will know themselves to be, test subjects of scientific experiments. Finally, they will be aware of the possibility that undetected genetic anomalies will be passed to their own children.
Risks of egg extraction
Egg extraction poses under-studied risks to women, including memory loss, bone ache, seizures, and Ovarian Hyperstimulation Syndrome. Mitochondria replacement research in the U.S. and U.K. has already required hundreds of eggs from women. Economically disadvantaged women are often specifically targeted as potential egg donors, while the risk to their bodies is routinely downplayed and follow-up care tends to be minimal. Many are concerned that the great need for eggs in order to carry out these techniques will lead to increased exploitation of egg donors. These concerns need to be taken into account when considering the advisability of mitochondria replacement.
[back to top]
Frequently Asked Questions
How many people would use mitochondria replacement?
The techniques that are being considered here will be of potential benefit to only a small number of people. Inherited disease caused by mitochondrial DNA of all kinds, including those not relevant to the proposed procedures, affects 1 in 5,000–10,000 people. Women who have inheritable mitochondrial disease and who want to have children have four other options to avoid passing on mutated mtDNA: adoption, egg donation, prenatal genetic diagnosis, and preimplantation genetic diagnosis. Only a very small number of women who have particularly complicated mutations would have reason to consider using one of the mtDNA techniques now being proposed. In the United Kingdom, for example, it has been estimated that this would number not more than ten to twenty families per year. Although the desire of these families to have a genetically related child is understandable, it needs to be balanced against the implications of opening the door to a new era in which human beings have become artifacts of genetic modification.
Can people use PGD to have a genetically related healthy child?
Some people who have mitochondrial disorders do currently make use of Preimplantation Genetic Diagnosis (PGD) to choose an embryo with a low level of mitochondrial mutations. An embryo with less than 18% of mutated mtDNA has a 95% or greater chance of being unaffected by mitochondrial disease, so the use of PGD to determine mutations in mtDNA comes close to eliminating a child's risk.
Is mitochondria donation similar to other kinds of donation?
The donation of mitochondria is markedly different from organ donation because it alters every part of a person’s existence as it is in continuous interaction with the rest of their DNA; it can have unforeseen complications later in life; and because it forever changes one’s genetic inheritance. It is also not a decision made for oneself as with using a donated organ. The resulting child would never be able to give free and informed consent for the procedure.
It is misleading to draw ethical, social or medical comparisons between mitochondria donation and organ donation.
How has the media covered the issue?
Many articles have referenced the fact that mitochondria replacement creates a "three-parent baby," but entirely neglect the fact that this technique is inheritable genetic modification. Additionally, there has been misleading information regarding the current uses, safety, and ramifications of mitochondria replacement. See here for common misconceptions that have proliferated in the media; see here for information about an article that continues to confuse readers because it is undated; and see here for coverage of a live debate that took place, in which one debater misleadingly used mitochondria replacement as an example of why we should oppose a ban on the genetic engineering of babies.
children already born years ago following ooplasmic transfer, a similar
germline modification technique? What happened with that?
There were up to 30 births that followed a process called ooplasmic transfer, which was undertaken by several fertility clinics in an attempt to help infertile women have a child, but these procedures were done without proper evidence of safety or efficacy and resulted in genetic abnormalities in at least some of the resulting children. The FDA shut down the operations in 2001 and the techniques have been abandoned.
How can I get involved?
Please contact CGS at info[AT]geneticsandsociety[DOT]org to find out more about mitochondria replacement, and about how you can make your voice heard in the growing policy debate.
[back to top]
Last modified November 12, 2013